Gentamicin in Cardiac Surgery
Summary
Surgical site infection (SSI) is a serious postoperative complication after cardiac surgery that have a negative impact on a patient's health and survival. This study aims to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI with monitoring to the effective therapeutic level.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
Outcome
Mixed primary results
paper Primary end-points: new/worsening renal impairment, surgical site infection (SSI), Clostridium difficile infection (CDI). PMID 23837413 ↗
paper New or worsening renal impairment was less frequent with gentamicin (4.3% group 1 vs. 3.4% group 2, p=NS). PMID 23837413 ↗
paper There were fewer wound infections in group 2: SSI 3.2% (group 1) versus 2.7% (group2) (p=NS); PMID 23837413 ↗
paper There were nine CDIs in group 1 compared with one in group 2 (p=0.02). PMID 23837413 ↗
Publications
- Results Ackah JK, Neal L, Marshall NR, Panahi P, Lloyd C, Rogers LJ. Antimicrobial prophylaxis in adult cardiac surgery in the United Kingdom and Republic of Ireland. J Infect Prev. 2021 Mar;22(2):83-90. doi: 10.1177/1757177420971850. Epub 2020 Nov 24.
- Results White RW, West R, Howard P, Sandoe J. Antimicrobial regime for cardiac surgery: the safety and effectiveness of short-course flucloxacillin (or teicoplanin) and gentamicin-based prophylaxis. J Card Surg. 2013 Sep;28(5):512-6. doi: 10.1111/jocs.12155. Epub 2013 Jul 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ceftriaxone | Other / unclassified | 1 g | — |
| Subject | Gentamicin | Small molecule | 80 mg | — |
| Background | FLOXACILLIN | Small molecule | 1 g | — |
Indications
No indication recorded.